AIM ImmunoTech CFO Departs, New Director Appointed, $10M Stock Sale
Ticker: AIM · Form: 8-K · Filed: Sep 12, 2024 · CIK: 946644
Sentiment: mixed
Topics: executive-departure, equity-sale, board-appointment
TL;DR
CFO out, new director in, and $10M stock sale announced by AIM ImmunoTech.
AI Summary
AIM ImmunoTech Inc. announced on September 11, 2024, the departure of its Chief Financial Officer, Elizabeth L. McGovern, effective September 10, 2024. The company also elected Dr. Michael T. Har-Ding as a new director and appointed him to the Audit Committee. Additionally, AIM ImmunoTech entered into a securities purchase agreement for the unregistered sale of approximately $10.0 million of its common stock.
Why It Matters
The departure of a CFO and a significant stock sale can impact investor confidence and the company's financial structure, while the appointment of a new director may signal strategic shifts.
Risk Assessment
Risk Level: medium — The departure of a key executive, coupled with an unregistered stock sale, introduces uncertainty regarding financial management and potential dilution.
Key Numbers
- $10.0M — Unregistered Stock Sale (Represents proceeds from the sale of common stock.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Elizabeth L. McGovern (person) — Chief Financial Officer who departed
- September 10, 2024 (date) — Effective date of CFO departure
- Dr. Michael T. Har-Ding (person) — Newly elected director
- $10.0 million (dollar_amount) — Amount of common stock sold
- September 11, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Financial Officer?
The filing does not specify a replacement for Elizabeth L. McGovern as CFO.
What is the effective date of Elizabeth L. McGovern's departure?
Elizabeth L. McGovern's departure was effective September 10, 2024.
What is the total value of the unregistered sale of equity securities?
The company entered into an agreement for the unregistered sale of approximately $10.0 million of its common stock.
What committee has Dr. Michael T. Har-Ding been appointed to?
Dr. Michael T. Har-Ding has been appointed to the Audit Committee.
What is the primary business of AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is in the business of biological products, specifically excluding diagnostic substances.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-09-12 16:45:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
- $750,000 — m compensation was further reduced from $750,000 to $650,000, with the reduced amount be
- $650,000 — on was further reduced from $750,000 to $650,000, with the reduced amount being paid in
- $100,000 — ed shares of our common stock valued at $100,000, such value equal to 100% of the closin
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 16KB
- ex10-2.htm (EX-10.2) — 15KB
- 0001493152-24-036060.txt ( ) — 248KB
- aim-20240911.xsd (EX-101.SCH) — 3KB
- aim-20240911_lab.xml (EX-101.LAB) — 33KB
- aim-20240911_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: September 12, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO